National Cancer Institute (NCI)
cancer.govLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,159
Capped at 5,000
Active
272
Phase 3
74
Total enrollment
809,032
Pipeline matrix
Showing 40 of 286 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Recombinant Human Papillomavirus Nonavalent Vaccine | — | — | — | — | 2 | ||
| Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed | — | — | — | — | — | 1 | |
| Recombinant Human Papillomavirus Bivalent Vaccine | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | 65 | |||
| Nivolumab | — | — | — | 32 | |||
| Cisplatin | — | — | — | 51 | |||
| Carboplatin | — | — | — | 46 | |||
| Pembrolizumab | — | — | — | 23 | |||
| Paclitaxel | — | — | — | 48 | |||
| Rituximab | — | — | — | 29 | |||
| Olaparib | — | — | — | 16 | |||
| Prednisone | — | — | — | 21 | |||
| Durvalumab | — | — | — | 10 | |||
| Etoposide | — | — | — | 31 | |||
| Dexamethasone | — | — | — | 17 | |||
| Lenalidomide | — | — | — | 15 | |||
| Atezolizumab | — | — | — | 13 | |||
| Venetoclax | — | — | — | 12 | |||
| Bevacizumab | — | — | — | 59 | |||
| Cytarabine | — | — | — | 25 | |||
| Gemcitabine | — | — | — | 12 | |||
| Cabozantinib S-malate | — | — | — | 11 | |||
| Ibrutinib | — | — | — | 7 | |||
| Doxorubicin Hydrochloride | — | — | — | 25 | |||
| Vincristine Sulfate | — | — | — | 16 | |||
| gemcitabine hydrochloride | — | — | — | 25 | |||
| Temozolomide | — | — | — | 25 | |||
| Methotrexate | — | — | — | 14 | |||
| Doxorubicin | — | — | — | 9 | |||
| Pegylated Liposomal Doxorubicin Hydrochloride | — | — | — | 9 | |||
| Vincristine | — | — | — | 7 | |||
| Melphalan | — | — | — | — | 7 | ||
| Blinatumomab | — | — | — | 5 | |||
| filgrastim | — | — | — | 27 | |||
| fluorouracil | — | — | — | 18 | |||
| Cediranib Maleate | — | — | — | 14 | |||
| Pemetrexed | — | — | — | 5 | |||
| Cediranib | — | — | — | — | 4 | ||
| erlotinib hydrochloride | — | — | — | 21 | |||
| leucovorin calcium | — | — | — | 16 |
246 more active programs hidden
Next readouts
- 2008-07-01
- 2008-11-30
- 2012-05-01
- 2012-12-31
- 2013-04-19
- 2014-01-07
- 2014-04-30
- 2014-07-01
- 2014-07-15
- 2015-08-14
Top conditions
- Unspecified Adult Solid Tumor, Protocol Specific42
- Breast Cancer37
- Lymphoma29
- Prostate Cancer25
- Advanced Malignant Solid Neoplasm25
- Recurrent Mantle Cell Lymphoma24
- Recurrent Small Lymphocytic Lymphoma22
- Ovarian Cancer22
Frequently asked questions about National Cancer Institute (NCI)
- How many clinical trials does National Cancer Institute (NCI) have on ClinicalTrials.gov?
- National Cancer Institute (NCI) is listed as the lead sponsor on 1,159 clinical trials in ClinicalTrials.gov, 272 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Cancer Institute (NCI)'s trials are in Phase 3?
- 74 of National Cancer Institute (NCI)'s trials are in Phase 3, spread across 286 active drug programs.
- What therapeutic areas does National Cancer Institute (NCI) focus on?
- National Cancer Institute (NCI)'s most-studied conditions on ClinicalTrials.gov are Unspecified Adult Solid Tumor, Protocol Specific, Breast Cancer, Lymphoma, Prostate Cancer, Advanced Malignant Solid Neoplasm.
- When are National Cancer Institute (NCI)'s next clinical trial readouts?
- National Cancer Institute (NCI) has 10 upcoming primary-completion readouts tracked here; the soonest is “Decitabine in Treating Patients With Myelofibrosis”, expected around 2008-07-01.